IDH1 and central nervous system cancer: To investigate the impact of co-occurring IDH1 and ATRX mutations on innate immune signaling in glioma, we generated CT2A cells expressing mutant IDH1R132H in both AtrxWT and Atrx-KO genetic backgrounds.